225. Congenital nephrogenic diabetes insipidus Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65
Congenital nephrogenic diabetes insipidus and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
ID | Diseases (Sorted by drug repositionability) |
---|---|
225 | Congenital nephrogenic diabetes insipidus |
86 | Pulmonary arterial hypertension |
13 | Multiple sclerosis/Neuromyelitis optica |
115 | Hereditary periodic paralysis |
154 | Epilepsy with continuous spikes and waves during slow sleep |
114 | Non-dystrophic myotonia syndrome |
230 | Alveolar hypoventilation syndrome |
155 | Acquired aphasia with convulsive disorder |
299 | Cystic fibrosis |
90 | Retinitis pigmentosa |
6 | Parkinson disease |
97 | Ulcerative colitis |
67 | Polycystic kidney disease |
51 | Scleroderma |
113 | Muscular dystrophy |
58 | Hypertrophic cardiomyopathy |
46 | Malignant rheumatoid arthritis |
337 | Homocystinuria |
282 | Congenital dyserythropoietic anemia |
77 | Growth hormone secreting pituitary adenoma |
294 | Congenital diaphragmatic hernia |
222 | Primary nephrotic syndrome |
75 | Cushing disease |
88 | Chronic thromboembolic pulmonary hypertension |
65 | Primary immunodeficiency |
210 | Single Ventricle |
49 | Systemic lupus erythematosus |
158 | Tuberous sclerosis |
96 | Crohn disease |
2 | Amyotrophic lateral sclerosis |
271 | Ankylosing spondylitis |
21 | Mitochondrial disease |
298 | Hereditary pancreatitis |
206 | Fragile X syndrome |
301 | Macular dystrophy |
84 | Sarcoidosis |
251 | Urea cycle disorder |
72 | Pituitary ADH secretion disorder |
71 | Idiopathic osteonecrosis of the femoral head |
265 | Lipodystrophy |